HC Wainwright & Co. Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has initiated coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and set a price target of $20 for the company's stock.
January 29, 2024 | 11:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CalciMedica receives a Buy rating from HC Wainwright & Co. with a price target of $20, indicating a positive outlook for the stock.
The initiation of coverage by an analyst with a Buy rating typically suggests a positive outlook on the stock, which can lead to increased investor interest and potentially a rise in stock price. The announcement of a price target significantly higher than the current trading price can further bolster investor confidence and drive short-term price movement upwards.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100